NOVOLIN R
(Human insulin)ApprovedSmall molecule
Novo NordiskNOVOLIN R is one of 226 small molecule programs targeting Insulin resistance. It is currently in Approved.
9
Indications
39
Total Trials
2
Active Trials
225
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1NOVOLIN R
Novo NordiskApproved
Jardiance
Boehringer IngelheimPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Glargine
Eli LillyPreclinical
Aurlumyn
BBTG International Inc.
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Acipimox
Boehringer IngelheimPreclinical
Antiplatelet Drug
FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Preclinical
GLP-1
RRigshospitalet, Denmark
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 1 Diabetes9 trials
Show 6 more trials
Type 2 Diabetes5 trials
Insulin resistance2 trials
Concentration2 trials
19 more indications
Prospective1 trial
Sympathetic Activity1 trial
Gestational Diabetes1 trial
Overweight1 trial
Insulin Sensitivity1 trial
Adolescent1 trial
Type 2 Diabetic Patients1 trial
Type 2 Diabetes Mellitus1 trial
Observational Study1 trial
Hospitalized Patients1 trial
ESS1 trial
Pemphigus1 trial
Effect of Topical Insulin on Healing Rate of Pemphigus Lesions
Completed·—·Phase 2·NCT07461103·20 enrolled
Diabetes Mellitus1 trial
Regulatory
FDA Approval Timeline[4]
Jun 25, 1991
NOVOLIN R
BLA BLA019938
Jun 25, 1991
NOVOLIN 70/30
BLA BLA019991
Jul 1, 1991
NOVOLIN N
BLA BLA019959
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Human insulin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company